Nautilus Biotechnology announced the expansion of its research and development senior leadership team with the appointment of Martin Huber, Ph.D., as Vice President, VP, of Biochemistry and Flow Cell Development. Dr. Huber brings to Nautilus over 20 years of experience in biotechnology start-ups both in Europe and the US, most recently as founder, CTO and, ultimately, CEO of Quantapore.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NAUT:
- Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development
- Nautilus Biotechnology Reports Third Quarter 2023 Financial Results
- Nautilus Biotechnology reports Q3 EPS (13c), consensus (17c)
- NAUT Upcoming Earnings Report: What to Expect?
- Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023
